RESEARCH at The Clatterbridge Cancer Centre into how the Covid-19 pandemic has affected people with blood cancer is to be expanded after a funding boost.
The UnCoVer study (Understanding the impact of SARS-CoV-2 infection in patients with blood cancer) has had a boost of £280,000 of competitive funding from Blood Cancer UK.
As part of the research, routinely-collected NHS data is being analysed to find out which blood cancer patients are most vulnerable to coronavirus.
According to those carrying out the study, many people with blood cancer - which includes leukaemia, lymphoma and myeloma - have a weakened immune system due to the underlying disease or its treatment.
As a result, they are not as good at fighting off the virus that causes COVID-19 compared with healthy people, and this has led to changes in some blood cancer treatments during the pandemic.
The new funding from Blood Cancer UK will allow the UnCoVer study to be extended by finding out how the treatment of blood cancer has changed during the pandemic.
It will also look at "the pros and cons" of different blood cancer treatments to see which of them works best in different situations.
The research will involve a network of collaborators from across the UK including not only senior blood cancer doctors but also patients and early career researchers.
The study is led by Prof Andy Pettitt and Prof Nagesh Kalakonda, Consultant Haemato-oncologists at The Clatterbridge Cancer Centre NHS Foundation Trust, and Prof Catrin Tudur-Smith, Professor of Medical Statistics at the University of Liverpool,
Prof Pettitt, who is also the Ronald Finn Chair of Experimental Medicine at the University of Liverpool, said: "We are delighted to receive this grant and grateful to Blood Cancer UK for awarding it.
"Understanding how blood cancer treatment and outcomes have changed during the COVID-19 pandemic is not only important in its own right but also provides an opportunity to study the effectiveness and side effects of new treatments that were rolled out during the pandemic.
"By shedding light on current practice and treatment outcomes, the research will highlight unmet needs and inequalities and show the difference between clinical trial data and real-world outcomes.
"This, in turn, will pave the way to future research that tackles these knowledge gaps and unmet needs.
"The research will also foster new collaborations, provide training opportunities for early career researchers and involve patients in the research at all levels.
"In doing so, it will benefit patients both directly and indirectly by helping to build a stronger and more patient-focused blood cancer research community."
Dr Maria Maguire, Clatterbridge's head of research governance and sponsorship, said: "We are very pleased that this grant application has been successful.
"The Clatterbridge Centre is taking the national lead in this area of research, which will have a direct benefit for our blood cancer patients."
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules here